The objective of this study was to compare the clinical efficacy of repeated doses of leucocyte-poor platelet-rich plasma (LP-PRP) plus hyaluronic acid (HA) to a single dose of autologous microfragmented adipose tissue (AMAT) injections in patients with early osteoarthritis (OA) symptoms. Eighty knees in 50 patients (mean age: 61.3 years) were randomly allocated into two equal groups in a nonblinded design and prospectively followed for 12 months. Group 1 received three intra-articular injections (1 month apart) using autologous LP-PRP+HA. Group 2 received a single dose of AMAT injection. Outcomes were measured by PROMs Tegner, Marx, visual analog scale, and Knee Injury and Osteoarthritis Outcome Score (KOOS) at 6 and 12 months. Both groups had significant clinical and functional improvement at 6 and 12 months. The differences between groups were statistically significant in Tegner score and KOOS symptoms (both P < 0.05) at 6 months in group 2. The test with statistically significant differences (P < 0.05) at 12 months was Tegner (P < 0.001), with group 2 having a higher median than group 1. LP-PRP+HA and AMAT lead to clinical and functional improvement at 6 and 12 months. AMAT showed better clinical results in Tegner and KOOS symptoms at 6 months and Tegner at 12 months. Understanding which therapy offers the most benefits with the least risk can significantly improve the quality of life for millions of people affected by OA. Long-term randomized controlled studies are needed to verify differences in efficacy.

中文翻译：

---

一项前瞻性研究比较白细胞贫血小板血浆联合透明质酸和自体微碎脂肪组织治疗早期膝关节骨性关节炎患者

本研究的目的是比较重复剂量的低白细胞富血小板血浆 (LP-PRP) 加透明质酸 (HA) 与单剂量自体微碎脂肪组织 (AMAT) 注射在早期患者中的临床疗效。骨关节炎（OA）症状。50 名患者（平均年龄：61.3 岁）中的 80 个膝关节以非盲法随机分为两组，前瞻性随访 12 个月。第 1 组使用自体 LP-PRP+HA 接受 3 次关节内注射（间隔 1 个月）。第 2 组接受单剂量的 AMAT 注射。结果通过 PROMs Tegner、Marx、视觉模拟量表以及 6 个月和 12 个月的膝关节损伤和骨关节炎结果评分 (KOOS) 来衡量。两组在 6 个月和 12 个月时都有显着的临床和功能改善。第 2 组 6 个月时P < 0.05)。12 个月时 差异有统计学意义 ( P  < 0.05) 的检验是 Tegner ( P  < 0.001)，第 2 组的中位数高于第 1 组。LP-PRP+HA 和AMAT 导致 6 个月和 12 个月时的临床和功能改善。AMAT 在 6 个月和 12 个月的 Tegner 和 KOOS 症状方面表现出更好的临床结果。了解哪种疗法以最小的风险提供最大的益处可以显着改善数百万受 OA 影响的人的生活质量。需要进行长期随机对照研究来验证疗效的差异。